Neal Walker - 01 Mar 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-fact
Issuer symbol
ACRS
Transactions as of
01 Mar 2023
Net transactions value
-$740,658
Form type
4
Filing time
03 Mar 2023, 19:37:20 UTC
Previous filing
03 Feb 2023
Next filing
05 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +96,150 +8.2% 1,271,913 01 Mar 2023 Direct F1
transaction ACRS Common Stock Options Exercise +18,275 +1.4% 1,290,188 01 Mar 2023 Direct F1
transaction ACRS Common Stock Options Exercise +24,000 +1.9% 1,314,188 01 Mar 2023 Direct F1
transaction ACRS Common Stock Sale $358,588 -29,000 -2.2% $12.37 1,285,188 02 Mar 2023 Direct F2, F3
transaction ACRS Common Stock Options Exercise +18,254 +1.4% 1,303,442 02 Mar 2023 Direct F1
transaction ACRS Common Stock Sale $382,070 -30,240 -2.3% $12.63 1,273,202 03 Mar 2023 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -96,150 -100% $0.000000* 0 01 Mar 2023 Common Stock 96,150 Direct F1, F6
transaction ACRS Restricted Stock Units Options Exercise $0 -18,275 -33% $0.000000 36,550 01 Mar 2023 Common Stock 18,275 Direct F1, F7
transaction ACRS Restricted Stock Units Options Exercise $0 -24,000 -25% $0.000000 72,000 01 Mar 2023 Common Stock 24,000 Direct F1, F8
transaction ACRS Restricted Stock Units Options Exercise $0 -18,254 -50% $0.000000 18,254 02 Mar 2023 Common Stock 18,254 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.
F5 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
F7 The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
F8 The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
F9 The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.